Natural killer (NK) cell-based therapies have made great progress in treating both hematological and solid tumors. Their unique mechanism of action does not rely on antigen presentation to recognize and eliminate tumor cells, making them a promising approach for cancer immunotherapy. In this review, we present a comprehensive summary of the latest clinical data of the novel NK cell-based therapies from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting the potential of these advancements to revolutionize the treatment of hematologic malignancies and solid tumors.

中文翻译：

---

针对血液系统和实体恶性肿瘤的新型基于自然杀伤细胞的疗法：ASCO 2024 的最新进展


基于自然杀伤 （NK） 细胞的疗法在治疗血液瘤和实体瘤方面都取得了长足的进步。它们独特的作用机制不依赖于抗原呈递来识别和消除肿瘤细胞，使其成为一种很有前途的癌症免疫疗法。在这篇综述中，我们全面总结了 2024 年美国临床肿瘤学会 （ASCO） 年会上基于 NK 细胞的新型疗法的最新临床数据，强调了这些进步彻底改变血液系统恶性肿瘤和实体瘤治疗的潜力。